Curatis Holding AG (CH:CURN)
:CURN
Want to see CH:CURN full AI Analyst Report?
CURN Stock Chart & Stats
CHF22.50
-CHF0.40(-1.75%)
―
--
Day’s Range― - ―
52-Week RangeCHF10.05 - CHF27.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.42K
Market Cap
CHF115.96M
Enterprise ValueCHF126.49M
Total Cash (Recent Filing)CHF894.00K
Total Debt (Recent Filing)CHF485.00K
Price to Earnings (P/E)―
Beta-1.03
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding5,155,765
10 Day Avg. Volume1,205
30 Day Avg. Volume1,417
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)1.30
Price to Sales (P/S)5.54
P/FCF Ratio-23.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.79
Revenue Forecast (FY)CHF99.00M
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ImprovementA ~57% revenue rebound and margin expansion to ~26% show improving product adoption and pricing. Sustained top-line momentum and rising gross margins create operating leverage potential, bolstering the company's ability to move toward durable profitability over several quarters if trends persist.
Balance Sheet StrengthA debt-free balance sheet with a sizable equity cushion provides durable financial flexibility to fund R&D, acquisitions, or commercialization without immediate refinancing pressure. This reduces bankruptcy and liquidity risk while enabling strategic investments during scaling.
Focused Pharma Business ModelA clear focus on acquisition, development and commercialization is a durable strategic model in specialty pharma: acquisitions can accelerate pipeline and commercialization leverages revenue durability from launched products. Over time this can create higher-margin, repeatable revenue streams if execution succeeds.
Bears Say
Negative Cash FlowPersistent operating and free cash flow deficits that worsened in 2025 indicate ongoing cash burn. This creates lasting dependency on external funding, risks dilution or restricted spending, and can constrain the firm's ability to sustain development and commercialization without secured capital.
Lack Of Sustainable ProfitabilityDespite revenue and margin improvements, core profitability remains negative and returns are below zero. Continued losses mean the company isn't yet self-funding; prolonged unprofitability increases refinancing and execution risk and delays the transition to a sustainable, capital-generating business.
Limited Scale & Execution RiskA very small headcount limits internal capacity for development, regulatory work and commercialization. Reliance on external partners or hires raises execution risk, can slow time-to-market, and may hinder scaling of manufacturing or commercial operations needed for long-term revenue growth.
Curatis Holding AG News
CURN FAQ
What was Curatis Holding AG’s price range in the past 12 months?
Curatis Holding AG lowest stock price was CHF10.05 and its highest was CHF27.90 in the past 12 months.
What is Curatis Holding AG’s market cap?
Curatis Holding AG’s market cap is CHF115.96M.
When is Curatis Holding AG’s upcoming earnings report date?
Curatis Holding AG’s upcoming earnings report date is Sep 02, 2026 which is in 83 days.
How were Curatis Holding AG’s earnings last quarter?
Curatis Holding AG released its earnings results on Mar 24, 2026. The company reported -CHF0.049 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.049.
Is Curatis Holding AG overvalued?
According to Wall Street analysts Curatis Holding AG’s price is currently Undervalued.
Does Curatis Holding AG pay dividends?
Curatis Holding AG does not currently pay dividends.
What is Curatis Holding AG’s EPS estimate?
Curatis Holding AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curatis Holding AG have?
Curatis Holding AG has 5,155,765 shares outstanding.
What happened to Curatis Holding AG’s price movement after its last earnings report?
Curatis Holding AG reported an EPS of -CHF0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Curatis Holding AG?
Currently, no hedge funds are holding shares in CH:CURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Options Prices
Currently, No data available
---